Q2 26 EPS
$-0.04
BEAT +73.63%
Est. $-0.15
Q2 26 Revenue
$382.5M
BEAT +0.78%
Est. $379.5M
vs S&P Since Q2 26
+21.5%
BEATING MARKET
TEM +25.1% vs S&P +3.5%
Market Reaction
Did TEM Beat Earnings? Q2 2026 Results
Tempus AI, Inc. Delivered a strong second quarter for fiscal 2026, beating Wall Street expectations on both the top and bottom lines and extending its consensus EPS beat streak to five consecutive quarters. The AI-driven healthcare company posted a n… Read more Tempus AI, Inc. Delivered a strong second quarter for fiscal 2026, beating Wall Street expectations on both the top and bottom lines and extending its consensus EPS beat streak to five consecutive quarters. The AI-driven healthcare company posted a non-GAAP loss of just $0.04 per share against a consensus estimate of $0.15, a 73.63% positive surprise, while revenue of $382.49 million edged past estimates by 0.78% and grew 21.6% year over year. The standout driver was Diagnostics, where oncology testing volumes accelerated to 31% growth and gross margin widened to 62.6% from 58.8% a year ago, while the Data and Applications segment contributed $93.15 million, up 28%, anchored by roughly $200 million in newly signed data licenses with partners including BioNTech and Daiichi Sankyo. Analysts tracking the stock have maintained bullish stances heading into the print, and management rewarded that confidence by raising full-year 2026 revenue guidance to $1.59 to $1.60 billion, implying approximately 25% annual growth, while holding its Adjusted EBITDA target of roughly $65 million.
Key Takeaways
- • Oncology volume growth of 31% year-over-year, accelerating from 28% last quarter
- • Data Licensing & Modeling (Insights) revenue grew 36% year-over-year
- • Diagnostics gross margin expansion to 62.6% from 58.8% year-over-year
- • $98.5 million in unrealized gains on marketable securities contributed to GAAP net income
TEM Forward Guidance & Outlook
Tempus increased its full-year 2026 revenue guidance to $1.595 to $1.605 billion, representing approximately 25% annual growth. The company continues to expect 2026 Adjusted EBITDA of approximately $65 million. Guidance assumes no impact from the pending Personalis acquisition, which is expected to close in late Q4 2026 or early 2027.
TEM YoY Financials
Q2 2026 vs Q2 2025, source: SEC Filings
TEM Revenue by Segment
With YoY comparisons, source: SEC Filings
“Q2 was another exceptional quarter for us. Our strategy is working given the investments we have made in AI over the past several years are driving some of the best growth rates we have seen in our two largest businesses - Oncology Diagnostics and Data Licensing.”
— Eric Lefkofsky, Q2 2026 Earnings Press Release
TEM Earnings Trends
TEM vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
TEM EPS Trend
Earnings per share: estimate vs actual
TEM Revenue Trend
Quarterly revenue: estimate vs actual
TEM Quarterly Results
6 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 BEAT | $-0.15 | $-0.04 | +73.63% | $382.5M | +0.78% |
| Q1 26 BEAT | $-0.20 | $-0.13 | +35.36% | $348.1M | +0.78% |
| Q4 25 BEAT FY | $-0.05 | $-0.04 | +22.03% | $367.2M | +1.05% |
| FY Full Year | — | $-0.61 | — | $1.27B | — |
| Q3 25 BEAT | $-0.18 | $-0.11 | +37.25% | $334.2M | +1.68% |
| Q2 25 BEAT | $-0.25 | $-0.25 | +1.15% | $314.6M | +5.67% |
| Q1 25 BEAT | $-0.27 | $-0.24 | +10.21% | $255.7M | +3.07% |